Paraneoplastic Vision Loss Evaluation [Test in Focus] - Insights
Andrew McKeon, M,B., B.Ch., M.D., provides an overview of Mayo Clinic Laboratories' new paraneoplastic vision loss evaluation — a test that can help direct a cancer diagnosis and guide treatment. He reviews why this test was developed, when...
Direct Ethanol Biomarker Testing: PETH - Insights
Paul Jannetto, Ph.D., describes Mayo Clinic Laboratories' new direct biomarker test for alcohol consumption. PETH is a blood test with a window of detection of about two to four weeks — compared with five days for urine-based screening for...
Staphylococcus species assay [Test in Focus] - Insights
Audrey Schuetz, M.D., discusses Mayo Clinic Laboratories' PCR assay that identifies two recently described staphylococcus species. The assay is unique in its ability to distinguish the new organisms from Staphylococcus aureus, providing...
SARS-CoV-2, Influenza A and B, and Respiratory Syncytial Virus (RSV) - Insights
Joseph Yao, M.D., explains how Mayo Clinic Laboratories’ SARS four-target test for viral respiratory disease can enhance patient care. The test detects RNA from SARS-CoV-2, influenza A, influenza B and respiratory syncytial virus, or RSV....
Neurofilament Light Chain (NFLC) - Insights
Alicia Algeciras, Ph.D., describes Mayo Clinic Laboratories’ new blood test to detect NFLC, or neurofilament light chain protein. NFLC is a biomarker for several neurodegenerative conditions. The new assay can determine if a patient’s...
TPNUQ genotyping assay - Insights
Ann Moyer, M.D., Ph.D., discusses TPNUQ, Mayo Clinic Laboratories' genotyping test for identifying patients at risk for thiopurine toxicity. Used prior to therapy initiation, our assay evaluates for nuances in both TPMT and NUDT15, which...
New gene panel enhances brain tumor profiles - Insights
Cristiane (Cris) Ida, M.D., explains how Mayo Clinic Laboratories' updated neuro-oncology gene panel provides more clinically relevant information for managing adult and pediatric brain tumors.
Nonradioactive assay helps diagnose heparin reaction - Insights
Rajiv Pruthi, M.B.B.S., explains how Mayo Clinic Laboratories’ serotonin release assay achieves high sensitivity and specificity while avoiding the use of radioactive materials. Serotonin release testing is an important tool in the...
Novel biomarkers added to movement disorders profile - Insights
Andrew McKeon, M.B., B.Ch., M.D., explains how Mayo Clinic Laboratories' expanded movement disorders panel better identifies autoimmune conditions to guide appropriate treatment.
Colorectal panel provides detailed cancer information - Insights
Rondell Graham, M.B.B.S., describes Mayo Clinic Laboratories' new colorectal cancer panel. The assay covers more genes to better inform decision-making about prognosis, targeted therapies and a hereditary cancer syndrome.